Drug Interactions that Matter: A Critical Reappraisal

Drugs

Volumn 36, Issue 1, 1988, Pages 83-110

  McInnes, Gordon T ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMIODARONE; AMPHETAMINE DERIVATIVE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; LITHIUM; METHADONE; METHOTREXATE; MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PHENYLBUTAZONE; QUINIDINE; SPIRONOLACTONE; SULFINPYRAZONE; THEOPHYLLINE; TOLBUTAMIDE;

DRUG INTERACTION; ENZYME INDUCTION; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RISK; SHORT SURVEY;

ANIMAL; DRUG INTERACTIONS; HUMAN; PHARMACOKINETICS;

EID: 0023785943     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198836010-00006     Document Type: Review

References (332)

1. Effects of propranolol on the hormonal and metabolic responses to insulin-induced hypoglycaemia
2. Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics
3. Interaction between debrisoquine and phenylephrine in man
4. Lithium and drug interactions
5. Interaction between debrisoquine and phenylephrine
6. Inhibition of tetracycline absorption by zinc
7. Hypoglycaemia induced by azapropazone-tolbutamide interaction
8. Amphetamine metabolism in amphetamine psychosis
9. The influence of sucralfate on ibuprofen absorption in healthy adult males
10. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy
11. The effect of rifampicin on the pharmacokinetics of ethinyloestradiol in women
12. Azathioprine-induced pancytopenia
13. Pregnancy attributable to interaction between tetracycline and oral contraceptives
14. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade
15. Drug interactions involving anticoagulant drugs
16. Effects of tetracyclines
17. Drug interaction — propranolol and cafergot
18. Dextrothyroxine for lowering serum cholesterol
19. Drug interactions and β-blockers
20. Digitalis intoxication
21. Interaction between digoxin and calcium antagonists and antiarrhythmic drugs
22. Rifampicin and methadone withdrawal
23. Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction
24. Carbamazepine-isoniazid interaction
25. Antagonism of bethanidine by mazindol
26. Adverse reactions to local anaesthetic/vasoconstrictor preparations
27. Interaction between sympathomimetic amines and anti-depressant agents in man
28. Anuria and acute tubular necrosis associated with gentamicin and cephalothin
29. Decreased phenytoin level during antineoplastic therapy: a case report
30. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man
31. The effect of rifampicin treatment on the metabolism of oestradiol and 17-ethinyloestradiol by human liver microsomes
32. Human cytochromes P-450
33. Phenytoin interference with dexamethasone
34. Drug interactions with oral anticoagulants
35. Interactions between oral contraceptives and other drugs
36. Drug interactions with warfarin: studies with dichloral-phenazone, chloral hydrate and phenazone (antipyrine)
37. Diphenylhydantoin intoxication attendant to slow inactivation of isoniazid
38. Interaction between clonidine and desipramine in man
39. Adverse drug interactions
40. First pass metabolism
41. Carbamazepine neurotoxicity precipitated by diltiazem
42. Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease
43. Effects of enzyme-induction on metabolism of prednisolone: clinical and laboratory study
44. Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma
45. Valproic acid and plasma levels of phenobarbital
46. Interaction of rifampicin and glucocorticoids. Adverse effect on renal allograft function
47. Cardiovascular responses to mianserin hydrochloride: a comparison with tricyclic anti-depressant drugs
48. The effect of phenobarbitone on blood levels of griseofulvin in man
49. Effect of cholestyramine and colestipol on the absorption of phenytoin
50. Mechanisms of amine transport in the cell membranes of the adrenergic nerves
51. Carbamazepine toxicity induced by concurrent erythromycin therapy
52. Alcohol-drugs interaction in man: alcohol and tolbutamide
53. Hazards of phenylephrine topical medication in persons taking propranolol
54. Interactions of guanethidine with adrenergic neurones
55. Apparent quinidine-induced digoxin toxicity after withdrawal of pentobarbital: case of sequential drug interactions
56. Pharmacokinetic-dynamic analysis of the indomethacin-frusemide interaction in man
57. Effect of diphenylhydantoin on cortisol kinetics in humans
58. Influence of pindolol (Visken) on respiratory function in 20 asthmatic patients
59. Renal effects of anti-inflammatory drugs
60. The clinical use of dextrothyroxine in hypercholesterolaemic states
61. Do anticonvulsants reduce the efficacy of oral contraceptives?
62. Theophylline determinations
63. Interaction between carbamazepine and propoxyphene in man
64. The effects of enzyme induction and enzyme inhibition of labetalol pharmacokinetics
65. Interactions between cyclosporin and rifampicin
66. Interaction of quinidine with anticonvulsant drugs
67. Observations in man of hypoglycaemia during selective and non-selective beta-blockade
68. Comparison of atenolol and propranolol during insulin-induced hypoglycemia
69. Prolongation of prothrombin time with cimetidine
70. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications
71. Treatment of gastric ulcer with carbenoxolone — antagonistic effect of spironolactone
72. Drug interactions
73. Angiotensin converting enzyme inhibitors and lithium treatment
74. Modification of antihypertensive effect of β-adrenoceptor blocking agents by inhibition of endogenous prostaglandin synthesis
75. Drug interactions with oral contraceptive steroids
76. Changes in cortisol metabolism following rifampicin therapy
77. Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase
78. Immediate cardiovascular responses to prazosin: effect of concurrent beta-blockers
79. Three antibiotic regimens in the treatment of infections in febrile granulocytopenic patients with cancer
80. Chlorpromazine reversal of the antihypertensive action of guanethidine
81. Gentamicin and cephalothin associated risks in blood urea nitrogen
82. Ketoconazole, cyclosporin metabolism and renal transplantation
83. Decreased phenytoin levels in antineoplastic therapy
84. The effect of metoprolol and practolol in lung function and blood pressure in hypertensive asthmatics
85. Adenine arabinoside and allopurinol — possible adverse drug interaction
86. Rifampicin-methadone interaction
87. Interaction between disopyramide and practolol
88. Drug interactions with cimetidine: an update
89. Adverse reactions to rifampicin in antituberculous regimens
90. Pancytopenia after combined treatment with allopurinol and azathioprine
91. Lidocaine-propranolol interactions
92. Potentiation of warfarin by azapropazone
93. Absorption of tetracyclines: interference by iron
94. Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program
95. Clinical pharmacokinetics of valproic acid
96. Antagonism of adrenergic neuron blockade in hypertensive subjects
97. Factors affecting the action of guanethidine on adrenergic neurones
98. Digoxin-quinidine interaction: pharmacokinetic evaluation
99. Inhibition of iron absorption by magnesium trisilicate
100. Primidone/dexamethasone interaction
101. Influence of dextropropoxyphene on steady-state serum levels and protein binding of three anti-epileptic drugs
102. Drug interactions with oral sulphonylurea hypoglycaemic drugs
103. Sulthiame (Ospolot) as inhibitor of diphenylhydantoin metabolism
104. Effect of diphenylhydantoin on the metabolism of dicoumarol in man
105. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin
106. Captopril — a preliminary review of its pharmacological properties and therapeutic efficacy
107. Rifampicin-induced non-responsiveness to corticosteroid treatment with nephrotic syndrome
108. Cimetidine interaction with warfarin
109. Cimetidine interaction with phenytoin
110. Effect of quinidine on plasma concentrations of digoxin
111. Fatal chlormethiazole poisoning in chronic alcoholics
112. Phenytoin intoxication induced by sulthiame in epileptic patients
113. Richens A Inhibition of phenytoin metabolism by sulthiame in epileptic patients
114. Major drug interactions: effect of liver disease, alcohol and malnutrition
115. Effect of smoking on theophylline disposition
116. Lithium toxicity enhanced by diuretics
117. Antacid therapy and drug kinetics
118. Drug metabolism in heavy consumers of ethyl alcohol
119. Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta-blockers with special reference to tocainide
120. Pharmacokinetics of oral 500mg pencillamine: effect of antacids on absorption
121. Guanethidine antagonism by antipsychotic drugs
122. Drug-drug and drug-disease interactions with non-steroidal anti-inflammatory drugs
123. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and para-aminosalicylic acid in man
124. Decreased theophylline half-life in smokers
125. Comprehensive drug surveillance
126. Kanamycin ototoxicity — possible potentiation by other drugs
127. Death due to isoniazid (INH) and phenytoin
128. Sodium dextro-thyroxine in coronary disease and hypercholesteremia
129. Warfarin and distalgesic interaction
130. Digitalis intoxication — a comparative study on the incidence of digitalis intoxication during the periods 1950–52 and 1964–66
131. Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations
132. Enhanced biotransformation of theophylline in marijuana and tobacco smokers
133. Mechanism of valproate-phenobarbitol interaction in epileptic patients
134. Increased rate of clearance of drugs from the circulation of alcoholics
135. Increased rate of tolbutamide metabolism in alcoholic patients
136. Diuretics are dangerous with lithium
137. Interactions and non-interactions with ranitidine
138. Dose dependence of the nifedipine/digoxin interaction
139. Influence of nisoldipine on haemodynamic effects and plasma levels of digoxin
140. Influence of verapamil on serum digoxin concentration
141. Acute renal failure after high doses of gentamicin and cephalothin
142. Effect of corticosteroids on blood salicylate concentrations
143. Phenytoin-valproic acid interaction in rhesus monkey
144. Hypoglycaemia precipitated by propranolol
145. Administration of erythromycin to patients on theophylline
146. Carbamazepine-danazol drug interaction: its mechanism examined by a stable isotope technique
147. Rifampicin-induced methadone withdrawal
148. Verapamil in the treatment of paroxysmal supraventricular trachycardia
149. Phenytoin-quinidine theophylline interaction
150. Verapamil plasma concentrations during treatment with cytostatic drugs
151. Biochemical and genetical factors regulating Dilantin metabolism in man
152. Diphenylhydantoin intoxication, a complication of isoniazid therapy
153. Comparison of trimethoprim alone and trimethoprim-sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to the selection of trimethoprim resistance
154. Rapid metabolism of cyclosporin and prednisone in kidney transplant patients on tuberculostatic treatment
155. Drug interactions involving appetite suppressants
156. Reduced renal clearance of digoxin during chronic quinidine administration
157. Interactions between quinidine and digoxin
158. Enhanced cardiac effect of digoxin during quinidine treatment
159. Drug interactions involving sympathomimetic amines, xanthines and anticholinergic drugs
160. Antagonism of guan-ethidine by imipramine
161. Treatment of penumococcic meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillins and aureomycin
162. Effect of sucralfate on the absorption and pharmacokinetics of chlorpropramide
163. Drug interactions with valproic acid
164. Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates and chlorothiazide treatment
165. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone
166. The effect of organic acids on renal clearance of methotrexate in man
167. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy
168. Modification by propranolol of cardiovascular effects of induced hypoglycaemia
169. Effects of indomethacin alone and during diuretic or β-adrenoceptor blockade therapy on blood pressure and the renin system in essential hypertension
170. Interaction of lithium and phenytoin
171. Clinial observations on possible barbiturate interference with anticoagulation
172. Lithium poisoning precipitated by diuretics
173. Contribution of prostaglandins to the systemic and renal vascular responses to frusemide in normal man
174. Diuretics during lithium therapy
175. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism
176. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction
177. Effect of cimetidine on carbamazepine auto- and heteroinduction in man
178. Rifampicin and cortisone replacement therapy
179. Inhibition of theophylline metabolism by long-term allopurinol administration
180. The effect of zinc sulphate and of bicitropeptide on tetracycline absorption
181. Phenytoin-theophylline interaction
182. The effects of erythromycin in patients treated with cyclosporin
183. Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia
184. Valproic acid in epilepsy: clinical and pharmacological effects
185. The effects of erythromycin on theophylline elimination in normal males
186. Drug use in the hospital: evaluation of determinants
187. Interaction between azaproprazone and warfarin
188. Chlormethiazole and alcohol: a lethal cocktail
189. Cardiovascular responses to verapamil and propranolol in hypertensive patients
190. The performance of clinics for outpatient control of anticoagulation
191. Pharmacology and clinical use of antimineralcorticoids
192. Intravenous verapamil during β-adrenoceptor blockade with propranolol
193. Cardiac arrest following chlormethiazole infusion in chronic alcoholics
194. Sotalol, hypokalaemia, syncope and torsade de pointes
195. Phenytoin/dexamethasone interaction: a clinical problem
196. Deafness following standard intravenous dose of ethacrynic acid
197. Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program
198. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination
199. Interaction of sulphinpyrazone with warfarin
200. Antagonism of hypotensive action of bethanidine by ‘common cold’ remedy
201. Antagonism of the action of guanethidine sulphate by desipramine HC1
202. Guanethidine and related agents, III: antagonism by drugs which inhibit the norepinephrine pump in man
203. Inhibition of hepatic microsomal drug metabolism by the immunosuppressive agent cyclosporin A
204. Amiodarone increases plasma digoxin concentrations
205. Mechanism of the inhibitory action of phenalzone on microsomal drug metabolism
206. Outbreak of unexpected reactions among epileptics taking isoniazid
207. Warfarin and phenytoin interaction
208. Biphasic sulphinpyrazone-warfarin interaction
209. Interference of iron with the absorption of tetracyclines in man
210. Interactions with the absorption of tetracyclines
211. Clinically significant sucralfate-warfarin interaction is not likely
212. Antipyrine analgesic in patients on antiepileptic drug therapy
213. Comparison of propranolol, metaprolol and acebutolol in insulin-induced hypoglycaemia
214. Drugs, disease and altered gastric emptying
215. Interactions between cephaloridine and frusemide in man
216. Interaction between estrogen and Dilantin in a menopausal woman
217. Drug interactions with guanethidine
218. Amiodarone-digoxin interaction: clinical and experimental observations
219. Frusemide and lithium toxicity
220. Drug interaction between sulthiame (Ospolot) and phenytoin in the treatment of epilepsy
221. Effect of Atromid and ethyl chloraphenocyisobutyrate on anticoagulant requirements
222. Interactions with sodium warfarin and rifampicin: studies in man
223. The stereoselective interaction of warfarin and metronidazole in man
224. Enantiomers of warfarin and phenobarbital
225. Warfarin and Distalgesic interaction
226. Effect of sodium dextrothyroxine in patients receiving anticoagulants
227. Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man
228. Phenobarbital-valproic acid interaction in normal man
229. Effect of nifedipine on digoxin kinetics in healthy subjects
230. Influence of verapamil on the inotropism and pharmacokinetics of digoxin
231. Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension
232. Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine
233. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects
234. Drug interactions involving drugs used in the treatment of epilepsy
235. Effectiveness of prednisolone during phenytoin therapy
236. Effect of prolonged thiazide treatment of renal lithium clearance
237. Evaluation of drug interactions
238. Awareness and experience of general practitioners of selected drug interactions
239. Clinical toxicity of theophylline in relation to cigarette smoking: a report from the Boston Collaborative Drug Surveillance Program
240. Effect of antibiotics on theophylline kinetics in humans
241. Drug adverse reactions and interactions involving sulfonamides, trimethoprim, nitrofurantoin, nalidixic acid, fusidic acid, polymixins and bacitracin
242. Carbamazepine-viloxazine interaction in patients with epilepsy
243. The haematological dangers of combined treatment with azathioprine and allopurinol
244. The influence of cigarette smoking and sex on the theophylline disposition
245. Interaction between azapropazone and warfarin
246. Selective cardiac sympathetic blockade as an adjunct to bronchodilator therapy
247. Effect of erythromycin on theophylline kinetics
248. Effect of erythromycin on cyclosporin levels
249. Cimetidine inhibits microsomal drug metabolism in the rat
250. Lithium interaction with sulindac and naproxen
251. Phenytoin-theophylline-quinidine interaction
252. Griseofulvin-phenobarbital interaction in man
253. The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis
254. Interaction of cimetidine with liver microsomes
255. Depression of theophylline elimination by erythromycin
256. Propranolol and hypoglycemia
257. Vincristine in the etiology of toxicity of high dose methotrexate therapy
258. Nifedipine and beta-blockade as a cause of heart failure
259. Observation in digitalis intoxication
260. Dissociation between free and bound phenytoin levels in the presence of valproic acid
261. Phenytoin intoxication during concurrent diazepam therapy
262. Interaction between carbamazepine and warfarin
263. Cyclosporin interactions with danazol and norethisterone
264. Amphetamine blood and urine levels in man
265. Interaction between oxprenolol and indomethacin in blood pressure in essential hypertensive patients
266. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin
267. Haemodynamic effects of verapamil and practolol in man
268. Interaction of rifampicin and chlorpropamide
269. Cimetidine: interaction with oral anticoagulants in man
270. The epidemiology of digoxin
271. Lithium-carbamazepine neurotoxicity and risk factors
272. Cimetidine potentiation of the hypoprothrombinaemic effect of warfarin
273. Hypertension and depression: interrelated problems in therapy
274. Antagonism of the anti-hypertensive action of bethanidine and debrisoquine by tricyclic antidepressants
275. The effect of sucralfate upon phenytoin absorption in man
276. Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility
277. Drug interactions involving infusion therapy
278. Change in receptor site affinity: a proposed explanation for the potentiating effect of D-throxine on the anticoagulant response to warfarin
279. Increased clearane of tolbutamide from the blood of asthmatic patients
280. Effect of N-phenylbarbital (Phetharbital) on the metabolism of testosterone and cortisol in man
281. Interactions of guanethidine and indirect-acting sympathomimetic amines
282. Drug interactions in patients on long-term oral anticoagulant and antihypertensive adrenergic neuron-blocking drugs
283. Suppression of renal excretion of digoxin in hypokalaemic patients
284. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy
285. Effects of diphenylhydantoin, phenobarbital and diazepam on the metabolism of methylprednisolone and its sodium succinate
286. Antagonism of certain effects of catecholamine depleting agents by anti-depressants and related drugs
287. Alteration of digitalis binding by quinidine: a mechanism of digitalis-quinidine interaction
288. The influence of a tricyclic antidepressive agent (proptriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man
289. Rifampicin and drug metabolism
290. Cimetidine interaction with carbamazepine
291. Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics
292. Interaction between warfarin and sulphamethoxazole
293. Monoamine oxidase inhibitors: a review
294. Drug interference with warfarin therapy
295. Decreased bioavailability of prednisolone due to antacids in patients with chronic active liver disease and in healthy volunteers
296. Interaction between phenytoin and the benzodiazepines
297. Carbamazepine intoxication caused by interaction with isoniazid
298. Concurrent steroid and rifampicin therapy
299. Severe peripheral ischaemia during concomitant use of beta-blockers and ergot alkaloids
300. Inhibition of propranolol metabolism by chlorpromazine
301. Effect of atenolol on ventilatory and cardiac function in asthma
302. Phenothiazine-induced phenytoin intoxication
303. Fenfluramine in obese patients on various antihypertensive drugs
304. Prevention of delayed graft function in cadaver kidney transplants by diltiazem
305. Interactions between digoxin and potassium-sparing diuretics
306. Clinically important interactions involving drugs used in the treatment of peptic ulcer
307. The adverse effect of anticonvulsant therapy on renal allograft survival
308. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin
309. Interactions of NSAIDs with diuretics and β-blockers: mechanisms and clinical implications
310. Initial dose of enalapril in hypertension
311. The effect of flucainide acetate, a new antiarrhythmic, on plasma digoxin levels
312. Dose-dependent kinetics of theophylline disposition in asthmatic children
313. Inhibition of theophylline clearance by troleandomycin
314. Interactions affecting drug absorption
315. Interference in the effect of dexamethasone by diphenylhydantoin
316. Effect of diphenylhydantoin on cortisol metabolism in man
317. The chlorpropamide alcohol flush
318. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics
319. Effect of erythromycin on carbamazepine kinetics
320. Guanethidine
321. Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus
322. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction
323. Carbamazepine-erythromycin interaction: case studies and clinical significance
324. Hyperkalaemia with cardiac arrhythmia: induction by salt substitutes, spironolactone and azotaemia
325. Lithium-methyldopa interaction
326. Inhibition of prostaglandin synthesis by indomethacin interests with antihypertensive effect of atenolol
327. Haemolysis after combined azathioprine-allopurinol therapy
328. Pharmacokinetic interactions with rifampicin
329. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol
330. Methotrexate-salicylate interaction: a clinical and experimental study